Connection

SANJEEV VASUDEVAN to Signal Transduction

This is a "connection" page, showing publications SANJEEV VASUDEVAN has written about Signal Transduction.
Connection Strength

0.158
  1. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014 Feb 20; 5:e1079.
    View in: PubMed
    Score: 0.046
  2. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
    View in: PubMed
    Score: 0.019
  3. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
    View in: PubMed
    Score: 0.017
  4. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget. 2017 Jan 03; 8(1):1555-1568.
    View in: PubMed
    Score: 0.014
  5. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480.
    View in: PubMed
    Score: 0.014
  6. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015 Aug 06; 6:e1841.
    View in: PubMed
    Score: 0.013
  7. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis. 2015 Jan; 20(1):50-62.
    View in: PubMed
    Score: 0.012
  8. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013 Oct 17; 4:e867.
    View in: PubMed
    Score: 0.011
  9. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis. 2013 Oct; 18(10):1224-34.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.